Uncategorized Archives - Page 6 of 7 - Fennec Pharmaceuticals : Fennec Pharmaceuticals

Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

Posted on May 8, 2020 (May 7, 2020) by mgowland

Research Triangle Park, N.C., May 8, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that in connection with its previously completed underwritten offering […]

Fennec Announces Closing of Public Offering

Posted on May 5, 2020 (May 4, 2020) by mgowland

Research Triangle Park, N.C., May 5, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the closing of its previously announced underwritten public offering […]

Fennec Announces Pricing of Public Offering

Posted on April 30, 2020 by mgowland

Research Triangle Park, N.C., April 30, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the pricing of its underwritten public offering of 4,800,000 common shares at […]

Fennec Announces Proposed Public Offering of Common Shares

Posted on April 29, 2020 by mgowland

Research Triangle Park, N.C., April 29, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that it intends to offer its common shares in an underwritten public […]

FENNEC PHARMACEUTICALS ANNOUNCES FDA FILING ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR PEDMARK™

Posted on April 13, 2020 by mgowland

~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ FDA Grants Priority Review and Sets a Prescription Drug User Fee Act (PDUFA) Target Action Date of August 10, 2020 ~ Research Triangle Park, NC, April 13, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: […]

FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARK™

Posted on March 5, 2020 (March 5, 2020) by mgowland

Research Triangle Park, NC, March 5, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,596,190 […]

Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate

Posted on February 28, 2020 (February 27, 2020) by mgowland

Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park, NC, Feb. 28, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the company’s Marketing Authorization Application (MAA) for its investigational drug, sodium thiosulfate (unique formulation) for infusion (tradename to be […]

FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2019 FINANCIAL RESULTS

Posted on February 14, 2020 (February 13, 2020) by mgowland

NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020 Commercial readiness activities in US underway for potential launch of PEDMARKTM, is approved, in the second half of 2020 Solid financial position with $13.7 million and no debt and the option to access $12.5 million in debt financing upon FDA approval of […]

FENNEC PHARMACEUTICALS COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK™ AND ALSO SUBMITS MARKETING AUTHORIZATION APPLICATION (MAA) TO EUROPEAN MEDICINES AGENCY

Posted on February 11, 2020 (February 10, 2020) by mgowland

PEDMARKTM[1] is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park, NC, Feb. 11, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (a unique […]

FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS

Posted on November 12, 2019 (November 7, 2019) by mgowland

NDA (New Drug Application) for PEDMARKTM to be completed in early 2020 Strong financial position with $15.2 million in cash and no debt Research Triangle Park, NC, November 12, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for […]